CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator - PubMed (original) (raw)
doi: 10.1038/ni1554. Epub 2008 Jan 13.
Affiliations
- PMID: 18193050
- DOI: 10.1038/ni1554
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator
Guifang Cai et al. Nat Immunol. 2008 Feb.
Erratum in
- Nat Immunol. 2008 May;9(5):567
Abstract
CD160, a glycosylphosphatidylinositol-anchored member of the immunoglobulin superfamily, is expressed on both cytolytic lymphocytes and some unstimulated CD4+ T cells. Here we show that CD160 expression was increased after activation of human CD4+ T cells and that crosslinking CD160 with monoclonal antibody strongly inhibited CD3- and CD28-mediated activation. We found that herpesvirus entry mediator (HVEM) was a ligand of CD160 that acted as a 'bidirectional switch' for T cell activation, producing a positive or negative outcome depending on the engagement of HVEM by CD160 and known HVEM ligands such as B and T lymphocyte attenuator (BTLA) and the T lymphocyte receptor LIGHT. Inhibition of CD4+ T cell activation by HVEM-transfected cells was dependent on CD160 and BTLA; when the cysteine-rich domain 1 of HVEM was deleted, this inhibition was lost, resulting in strong T cell activation. CD160 thus serves as a negative regulator of CD4+ T cell activation through its interaction with HVEM.
Comment in
- CD160 and BTLA: LIGHTs out for CD4+ T cells.
Kaye J. Kaye J. Nat Immunol. 2008 Feb;9(2):122-4. doi: 10.1038/ni0208-122. Nat Immunol. 2008. PMID: 18204424 No abstract available.
Similar articles
- Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R, Kajikawa M, Shiroishi M, Kuroki K, Maenaka K. Kojima R, et al. J Mol Biol. 2011 Nov 4;413(4):762-72. doi: 10.1016/j.jmb.2011.09.018. Epub 2011 Sep 19. J Mol Biol. 2011. PMID: 21959263 - The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G, Freeman GJ. Cai G, et al. Immunol Rev. 2009 May;229(1):244-58. doi: 10.1111/j.1600-065X.2009.00783.x. Immunol Rev. 2009. PMID: 19426226 Review. - CD160 and BTLA: LIGHTs out for CD4+ T cells.
Kaye J. Kaye J. Nat Immunol. 2008 Feb;9(2):122-4. doi: 10.1038/ni0208-122. Nat Immunol. 2008. PMID: 18204424 No abstract available. - A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, Eaton DL. Gonzalez LC, et al. Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1116-21. doi: 10.1073/pnas.0409071102. Epub 2005 Jan 12. Proc Natl Acad Sci U S A. 2005. PMID: 15647361 Free PMC article. - BTLA and HVEM cross talk regulates inhibition and costimulation.
Gavrieli M, Sedy J, Nelson CA, Murphy KM. Gavrieli M, et al. Adv Immunol. 2006;92:157-85. doi: 10.1016/S0065-2776(06)92004-5. Adv Immunol. 2006. PMID: 17145304 Review.
Cited by
- The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma.
Jiang G, Wang Z, Cheng Z, Wang W, Lu S, Zhang Z, Anene CA, Khan F, Chen Y, Bailey E, Xu H, Dong Y, Chen P, Zhang Z, Gao D, Wang Z, Miao J, Xue X, Wang P, Zhang L, Gangeswaran R, Liu P, Chard Dunmall LS, Li J, Guo Y, Dong J, Lemoine NR, Li W, Wang J, Wang Y. Jiang G, et al. Nat Commun. 2024 Oct 18;15(1):8988. doi: 10.1038/s41467-024-53164-x. Nat Commun. 2024. PMID: 39419971 Free PMC article. - Multilayered Computational Framework for Designing Peptide Inhibitors of HVEM-LIGHT Interaction.
Ciura P, Smardz P, Spodzieja M, Sieradzan AK, Krupa P. Ciura P, et al. J Phys Chem B. 2024 Jul 18;128(28):6770-6785. doi: 10.1021/acs.jpcb.4c02255. Epub 2024 Jul 3. J Phys Chem B. 2024. PMID: 38958133 Free PMC article. - The Potential Significance of the EMILIN3 Gene in Augmenting the Aggressiveness of Low-Grade Gliomas is Noteworthy.
Wang LA, Zheng Z, Zheng J, Zhang G, Wang Z. Wang LA, et al. Cancer Manag Res. 2024 Jun 26;16:711-730. doi: 10.2147/CMAR.S463694. eCollection 2024. Cancer Manag Res. 2024. PMID: 38952353 Free PMC article. - Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
Dalle S, Verronese E, N'Kodia A, Bardin C, Rodriguez C, Andrieu T, Eberhardt A, Chemin G, Hasan U, Le-Bouar M, Caramel J, Amini-Adle M, Bendriss-Vermare N, Dubois B, Caux C, Ménétrier-Caux C. Dalle S, et al. Oncoimmunology. 2024 Jun 26;13(1):2372118. doi: 10.1080/2162402X.2024.2372118. eCollection 2024. Oncoimmunology. 2024. PMID: 38939518 Free PMC article. Clinical Trial. - HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function.
Liu Y, Wang L, Li Y, Zhong C, Wang X, Wang X, Xia Z, Liao J, Huang C, Mao C, Feng Y, Luo C, Mai W, Song H, Li H, Bao L, Chen D, Sheng Y, Zhang H, Wei X, Chen J, Yi W. Liu Y, et al. Cell Oncol (Dordr). 2024 Oct;47(5):1779-1796. doi: 10.1007/s13402-024-00959-1. Epub 2024 May 29. Cell Oncol (Dordr). 2024. PMID: 38809326
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous